Hemoglobin A1c (HbA1c) is a valuable diagnostic and prognostic marker of glycemic control in patients with diabetes that has been validated in clinical trials to correlate with diabetes-related complications.1–3
Hemoglobin A1c is hemoglobin that is glycated at the N-terminal valine residue of the β chain of adult hemoglobin.4 The hemoglobin molecule consists of an iron-containing heme ring and 4 globin chains. The globin chains determine the hemoglobin type. Adult hemoglobin consists of 2 α and 2 β chains and represents 97% of total hemoglobin.4 Hemoglobinopathies are genetic hemoglobin disorders that either result in the production of an abnormally low quantity of a globin chain (thalassemia) or the production of structurally variant hemoglobin. The most common structural hemoglobin variants include the following: hemoglobin S (also known as sickle cell hemoglobin), which is found in 6% to 9% of African Americans; hemoglobin C, which is found in 2.3% of African Americans; and hemoglobin E, which is found in up to 30% of Southeast Asians.5,6
As erythrocytes have an average life span of 120 days, HbA1c is a useful measure of glycemic control over the preceding 3 months with an emphasis on the preceding 30 days.7 However, a number of conditions can affect its reliability.
Case 1
A 58-year-old man presented to the emergency department with a 2-week history of fatigue, polyuria, and polydipsia. Past medical history included sickle cell disease (also known as hemoglobin SC disease), with hemoglobin S variant inherited from one parent, and hemoglobin C variant from the other. Investigations showed a blood glucose level of 56.3 mmol/L and a pH level of 7.32. There was evidence of hemolytic anemia, with laboratory values revealing a hemoglobin level of 78 g/L, total bilirubin level of 49.1 µmol/L, and lactate dehydrogenase level of 11.44 µkat/L (685 U/L). He was treated with intravenous fluids and insulin, and transitioned to multiple daily injections of insulin. Initial HbA1c testing by high-performance liquid chromatography was not done owing to “interfering, unknown substances.” His HbA1c level over the next 2 years was consistently below 6.0%. His multiple daily injections were stopped because of perceived overtreatment. He presented to the emergency department months later with symptomatic hyperglycemia. Self-monitored blood glucose (SMBG) levels were between 18 and 30 mmol/L. His insulin was restarted.
Case 2
A 71-year-old woman with type 2 diabetes taking basal and bolus insulin was assessed in clinic. Past medical history included chronic kidney disease (CKD), nonalcoholic steatohepatitis, and iron deficiency anemia due to chronic gastrointestinal bleeding. She required frequent iron infusions and packed red blood cell transfusions. Recent bloodwork revealed the following values: HbA1c level of 6.0%, hemoglobin level of 75 g/L, reticulocyte count of 175, and ferritin level of 236 pmol/L (105 µg/L). Fasting SMBG levels were 9 to 15 mmol/L, which were inconsistent with the HbA1c value.
Discussion
Hemoglobin A1c is a guideline-recommended test for diagnosis and follow-up in patients with diabetes.8 There are 2 different methods of measurement. One method, high-performance liquid chromatography, detects the difference in ionic charge of glycated and nonglycated hemoglobin.9 The second method, immunoassays, uses antibodies to recognize changes in the structure of the glycated molecule.10
Although there has been improvement in the accuracy and reliability of measuring HbA1c, the test can be affected by certain conditions.11–13 Conditions that prolong the life of erythrocytes or are associated with decreased erythrocyte turnover lead to increased exposure of cells to glucose and falsely high HbA1c results14; examples include iron deficiency anemia, B12 deficiency anemia, folate deficiency anemia, chronic alcohol use, and asplenia.14 Conditions that shorten the life of erythrocytes or are associated with increased erythrocyte turnover lead to reduced exposure of cells to glucose and falsely low HbA1c results 14; examples include acute and chronic blood loss, hemolytic anemia, splenomegaly, and pregnancy.14
Hemoglobinopathies can affect HbA1c by altering glycation, interfering with the assay, or causing erythrocytes to be more prone to hemolysis.4 Therefore, hemoglobinopathies can lead to falsely high or low measurements depending on the variant, the method, and the specific assay used.14 For example, in β thalassemia there is a high concentration of fetal hemoglobin (HbF), which consists of 2 α and 2 γ chains. Certain immunoassays specifically identify the β chain and will not detect the glycated γ chain that is seen at high levels of HbF, producing a falsely low HbA1c result. This is a known limitation of immunoassays, especially at a HbF level greater than 10%.15
The NGSP, previously known as the National Glycohemoglobin Standardization Program, provides an overview of various HbA1c assays and possible interference with hemoglobin variants.16 Our local laboratories (London, Ont) use a test that is not affected by common hemoglobin variants such as hemoglobins S, E, C, and D.16
Chronic kidney disease presents a challenge for measuring HbA1c, particularly when the estimated glomerular filtration rate is less than 30 mL/min per 1.73 m2.17–20 These patients have uremia and anemia of multifactorial causes (eg, iron deficiency, erythropoietin deficiency, and decrease in erythrocyte survival). Uremia leads to the formation of carbamylated hemoglobin, which can interfere with certain measurement methods.4 Uremia can also shorten the life span of erythrocytes.17 In addition, patients with CKD frequently receive erythropoietin to increase erythrocyte production, which can lead to falsely low HbA1c results. 17,18 Therefore, CKD makes HbA1c measurements unreliable.
Alternative biomarkers to HbA1c include fructosamine, glycated albumin, and plasma 1,5-anhydroglucitol levels. However, only HbA1c has been validated in randomized controlled trials to predict diabetes-related complications.5,14 The widespread use of alternative biomarkers is not established and is not currently recommended by Canadian guidelines.21
Patient 1 had sickle cell disease (hemoglobin SC disease) causing hemolytic anemia, which led to a falsely low HbA1c result. Whether the more common sickle cell trait (also known as hemoglobin AS) affects HbA1c is inconclusive. A retrospective cohort study of 4620 African Americans found that sickle cell trait significantly lowered HbA1c results compared with individuals without sickle cell trait (5.72% vs 6.01% [mean HbA1c difference of −0.29%; 95% CI −0.35% to −0.23%]).22 However, 2 older studies did not find an effect of sickle cell trait on HbA1c.23,24
Patient 2 had considerable anemia due to chronic gastrointestinal bleeding and CKD, which led to a falsely low HbA1c result. However, iron deficiency leads to reduced erythrocyte production and reduced erythrocyte turnover. This allows more time for glycation to occur and reveals a falsely high HbA1c result. A systematic review found falsely high HbA1c values in iron deficiency anemia.25 The discrepancy was estimated to be less than 0.5%. However, some studies looking at HbA1c values after treatment of iron deficiency anemia demonstrated a significant reduction in HbA1c values of 1.2% (P < .001).25
Not every patient with a condition that can affect HbA1c levels will have unreliable test results. However, family physicians should be aware of the possible limitations of the test. Periodic evaluation of SMBG readings is important to ensure concordance with HbA1c measurements. Discordant results should prompt a venous fasting blood glucose test to ensure meter accuracy.7 If SMBG readings are accurate, an evaluation of possible conditions that can affect HbA1c is warranted.
Self-monitored blood glucose remains a valuable tool in diabetes management. Instructing patients to complete SMBG readings as dictated by the severity of their diabetes or medication regimen is crucial, especially when HbA1c measurement is unreliable, in order to evaluate glycemic control. More advanced monitoring options such as continuous glucose monitoring or flash glucose monitoring can also be considered.26
Conclusion
Hemoglobin A1c is a marker of glycemic control and has been correlated with diabetes-related complications. However, there are conditions that can affect the reliability of HbA1c measurements, which might also affect clinical decision making. Health care providers should be aware of the limitations of this blood test.
Notes
Editor’s key points
▸ Hemoglobin A1c (HbA1c) is a valuable diagnostic and prognostic marker of glycemic control in patients with diabetes. However, there are conditions that can affect the reliability of HbA1c measurement (eg, chronic kidney disease, anemia, and hemoglobinopathy), so it is important to be aware of this blood test’s limitations.
▸ Erythrocytes have an average life span of 120 days. Conditions that prolong the life of erythrocytes or are associated with decreased erythrocyte turnover will lead to increased exposure of cells to glucose and falsely high HbA1c results; conditions that shorten the life of erythrocytes or are associated with increased erythrocyte turnover will lead to reduced exposure of cells to glucose and falsely low HbA1c results.
▸ The patients presented in this case report had conditions that led to falsely low HbA1c results; however, not all patients with conditions that can affect HbA1c levels will have unreliable test results. Periodic evaluation of self-monitored blood glucose readings is important to ensure concordance with HbA1c results. Discordant results should prompt a venous fasting blood glucose test to ensure meter accuracy. If self-monitored blood glucose readings are accurate, an evaluation of possible conditions that can affect HbA1c is warranted.
Points de repère du rédacteur
▸ L’hémoglobine A1c (HbA1c) est un précieux marqueur diagnostique et pronostique du contrôle de la glycémie chez les patients diabétiques. Par ailleurs, des problèmes peuvent affecter la fiabilité de la mesure de l’HbA1c (p. ex. néphropathie chronique, anémie, hémoglobinopathie), et il importe donc d’être conscient des limites de ces analyses sanguines.
▸ La durée moyenne de vie des érythrocytes se situe à 120 jours. Les conditions qui prolongent la vie des érythrocytes ou qui sont associées à une réduction de leur renouvellement entraîneront une augmentation de l’exposition des cellules au glucose, ainsi que des résultats faussement élevés de l’HbA1c; les conditions reliées à une réduction de la durée de vie des érythrocytes ou associées à leur renouvellement plus rapide réduiront l’exposition des cellules au glucose, d’où des mesures faussement basses de l’HbA1c.
▸ Les patients présentés dans ce rapport de cas avaient des problèmes qui se sont traduits par des résultats faussement bas de l’HbA1c; par contre, tous les patients dont les conditions peuvent affecter les taux d’HbA1c n’auront pas nécessairement des résultats de tests non fiables. Il est important de procéder à une évaluation périodique des lectures de la glycémie automesurée pour s’assurer qu’elles correspondent avec les résultats de la mesure de l’HbA1c. Si les résultats ne concordent pas, il faut procéder à une analyse de la glycémie veineuse à jeun pour assurer l’exactitude des mesures. Si les lectures de la glycémie faites par le patient sont exactes, il y a lieu d’évaluer les éventuelles conditions susceptibles d’affecter l’HbA1c.
Footnotes
Competing interests
None declared
This article has been peer reviewed.
Cet article a fait l’objet d’une révision par des pairs.
- Copyright© the College of Family Physicians of Canada
References
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.